55
Participants
Start Date
September 30, 2013
Primary Completion Date
June 30, 2016
Study Completion Date
June 30, 2016
defactinib (VS-6063)
University of Pittsburgh Medical Center Cancer Center, Pittsburgh
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore
Winship Cancer Institute of Emory University, Atlanta
Sarah Cannon Research Institute, Nashville
Washington University School of Medicine, St Louis
University of Colorado Cancer Center, Anschutz Medical Campus, Denver
Knight Cancer Institute, Oregon Health and Science University, Portland
University of Texas Southwestern Medical Center, Dallas
The University of Texas Health Science Center at San Antonio, San Antonio
Verastem, Inc.
INDUSTRY